BR0201889A - Vacinas de ige não-anafilactogênicas - Google Patents

Vacinas de ige não-anafilactogênicas

Info

Publication number
BR0201889A
BR0201889A BR0201889-6A BR0201889A BR0201889A BR 0201889 A BR0201889 A BR 0201889A BR 0201889 A BR0201889 A BR 0201889A BR 0201889 A BR0201889 A BR 0201889A
Authority
BR
Brazil
Prior art keywords
ige
vaccines
prevention
treatment
provides compositions
Prior art date
Application number
BR0201889-6A
Other languages
English (en)
Inventor
Mohamad Ali Morsey
Tracy Michelle Brown
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0201889A publication Critical patent/BR0201889A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"VACINAS DE IgE NãO-ANAFILACTOGêNICAS". O presente invento proporciona composições e métodos para a utilização de peptídeos antigênicos derivados da parte Fc da cadeia pesada epsílon de moléculas de IgE de duas espécies não-relacionadas como vacinas para o tratamento e prevenção de distúrbios alérgicos IgE-mediados. Em particular, a invenção proporciona composições para o tratamento e prevenção de distúrbios alérgicos IgE-mediado, compreendendo uma quantidade imunogênica de um ou mais peptídeos antigênicos.
BR0201889-6A 2001-05-22 2002-05-21 Vacinas de ige não-anafilactogênicas BR0201889A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29263801P 2001-05-22 2001-05-22

Publications (1)

Publication Number Publication Date
BR0201889A true BR0201889A (pt) 2004-04-13

Family

ID=23125524

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0201889-6A BR0201889A (pt) 2001-05-22 2002-05-21 Vacinas de ige não-anafilactogênicas

Country Status (6)

Country Link
US (3) US6974572B2 (pt)
EP (1) EP1262491A3 (pt)
JP (3) JP2003047482A (pt)
BR (1) BR0201889A (pt)
CA (1) CA2383004A1 (pt)
MX (1) MXPA02005133A (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887472B2 (en) * 2000-08-30 2005-05-03 Pfizer Inc. Anti-IgE vaccines
JP2003047482A (ja) * 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性ＩｇＥワクチン
GB0209878D0 (en) * 2002-04-30 2002-06-05 Glaxosmithkline Biolog Sa Vaccine
US7232898B2 (en) 2002-05-21 2007-06-19 Resistentia Pharmaceuticals Ab Chimeric IgE polypeptides and host cells
JP2008507474A (ja) * 2004-02-02 2008-03-13 タノックス インコーポレイテッド 新規のＩｇＥエピトープの同定
ES2779992T3 (es) 2005-12-20 2020-08-21 Univ Duke Métodos y composiciones para suministrar agentes activos con propiedades farmacológicas potenciadas
NZ573327A (en) * 2006-06-05 2012-07-27 Ocean Nutrition Canada Ltd Microcapsules with improved shells
US9187553B2 (en) * 2012-01-25 2015-11-17 Swey-Shen Chen Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold
JP5918851B2 (ja) * 2012-06-18 2016-05-18 日本全薬工業株式会社 ＩｇＥペプチドワクチン
CN107177613A (zh) * 2017-07-18 2017-09-19 哈尔滨紫霞生物科技有限公司 一种提高重组猪干扰素‑γ融合蛋白抗病毒活性的方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3668827D1 (de) 1986-03-11 1990-03-15 Lanfranco Anzani Mit einem autoklav zum vulkanisieren von kautschukkomponenten ausgestattete anlage zur kontinuierlichen fertigung von gegenstaenden.
JPS63225397A (ja) 1986-10-03 1988-09-20 Dainippon Pharmaceut Co Ltd 抗アレルギー作用を有する新規ペプチド
GB8913737D0 (en) 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment
SE466259B (sv) * 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
AU668870B2 (en) 1991-05-14 1996-05-23 Targetech, Inc Targeted delivery of genes encoding immunogenic proteins
AU2160992A (en) 1991-06-05 1993-01-12 Board Of Regents Acting For And On Behalf Of The University Of Michigan, The Targeted delivery of genes encoding secretory proteins
SE9102808L (sv) * 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
AU3434393A (en) 1992-01-17 1993-08-03 Regents Of The University Of Michigan, The Targeted virus
CA2133411A1 (en) 1992-04-03 1993-10-14 Alexander T. YOUNG Gene therapy using targeted viral vectors
JP3789930B2 (ja) 1992-10-09 2006-06-28 アドバンスド ティシュー サイエンシズ，インコーポレーテッド 肝予備細胞
JPH09510975A (ja) * 1994-03-28 1997-11-04 ユナイテッド・バイオメディカル・インコーポレイテッド アレルギー治療用合成ペプチドベース免疫原
US5629415A (en) * 1994-11-09 1997-05-13 Merck & Co., Inc. DNA encoding canine immunoglobulin E
HUP9901109A3 (en) 1996-03-01 1999-11-29 Novartis Ag Peptide immunogens for vaccination against and treatment of allergy
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
US6913749B2 (en) * 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
MXPA01008612A (es) * 1999-02-25 2003-06-24 Smithkline Beecham Biolog Epitopos o mimotopos derivados de los dominos c-epsilon-3 o c-epsilon-4 de ige, antagonistas de los mismos y sus usos terapeuticos.
US6887472B2 (en) * 2000-08-30 2005-05-03 Pfizer Inc. Anti-IgE vaccines
JP2003047482A (ja) * 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性ＩｇＥワクチン

Also Published As

Publication number Publication date
MXPA02005133A (es) 2002-12-05
US7420047B2 (en) 2008-09-02
JP2006254922A (ja) 2006-09-28
US6974572B2 (en) 2005-12-13
US20080193439A1 (en) 2008-08-14
EP1262491A3 (en) 2003-02-05
US20030096369A1 (en) 2003-05-22
CA2383004A1 (en) 2002-11-22
JP2006199701A (ja) 2006-08-03
EP1262491A2 (en) 2002-12-04
US20060002945A1 (en) 2006-01-05
JP2003047482A (ja) 2003-02-18

Similar Documents

Publication Publication Date Title
EP1609468A3 (en) A composition on the basis of a sulfur-containing antioxidant and its use for the manufacture of a medicament for treating mucositis
DE60314633D1 (de) Substituierte 1,3-diphenylprop-2-en-1-on derivate, deren herstellung und anwendungen
EP1195161A3 (en) Anti-IgE vaccines
WO2007053189A3 (en) Compositions and methods for altering immune function
NO20034056D0 (no) Proliferative sykdommer
ATE536188T1 (de) Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
NO20055202L (no) Hoykonsentrasjonsantistoff og proteinformuleringer
CY1105349T1 (el) Θειαζολυλ-αναστολεις τυροκινασεων της οικογενειας tec
BRPI0514395A (pt) uso terapêutico de inibidores de rtp801
DE60232660D1 (de) Humane dr4-antikörper und deren anwendungen
BRPI0410503B8 (pt) composição tópica e uso da composição
WO2002094228A8 (en) Prevention and treatment of allergies by helminthic regulation of ige
BRPI0414481A (pt) métodos de tratamento ou de prevenção da sìndrome das pernas inquietas em um paciente e de melhoria do sono em um paciente com sìndrome das pernas inquietas, e, composição farmacêutica
ATE546153T1 (de) Kombinationen von tumor-assoziierten antigenen zur behandlung von verschiedenen krebstypen
WO2007056142A3 (en) Methods of preventing the serotonin syndrome and compositions for use therefor
BR0201889A (pt) Vacinas de ige não-anafilactogênicas
BR0201862A (pt) Composições e métodos para tratar ou prevenir convulsões ou ataques apoplécticos
ATE466585T1 (de) Präparationen grampositiver bakterien zur behandlung von krankheiten mit immunfehlregulation
PT1228028E (pt) Sais de hidroxieicosatetraeniato, composicoes e metodos para utilizacao no tratamento de perturbacoes da secura ocular
ATE459353T1 (de) Gaboxadol zur behandlung von depressionen und anderen affektiven störungen
DE60231616D1 (de) Mittel zur verhinderung und behandlung von sexuell übertragenen krankheiten-i
BR0210650A (pt) Tablete, e, uso do mesmo
BRPI0508795A (pt) composição de tratamento capilar, uso da composição, método de tratamento de cabelos e método de fabricação de composição de tratamento capilar
BRPI0411176A (pt) combinação farmacêutica consistindo de modafinil e outra droga
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A A NUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2103 DE 26/04/2011.